Saltar al contenido
Merck

TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.

Neuron (2018-03-09)
Yingjun Zhao, Xilin Wu, Xiaoguang Li, Lu-Lin Jiang, Xun Gui, Yan Liu, Yu Sun, Bing Zhu, Juan C Piña-Crespo, Muxian Zhang, Ningyan Zhang, Xiaochun Chen, Guojun Bu, Zhiqiang An, Timothy Y Huang, Huaxi Xu
RESUMEN

Mutations in triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to increased Alzheimer's disease (AD) risk. Neurobiological functions of TREM2 and its pathophysiological ligands remain elusive. Here we found that TREM2 directly binds to β-amyloid (Aβ) oligomers with nanomolar affinity, whereas AD-associated TREM2 mutations reduce Aβ binding. TREM2 deficiency impairs Aβ degradation in primary microglial culture and mouse brain. Aβ-induced microglial depolarization, K+ inward current induction, cytokine expression and secretion, migration, proliferation, apoptosis, and morphological changes are dependent on TREM2. In addition, TREM2 interaction with its signaling adaptor DAP12 is enhanced by Aβ, regulating downstream phosphorylation of SYK and GSK3β. Our data demonstrate TREM2 as a microglial Aβ receptor transducing physiological and AD-related pathological effects associated with Aβ.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
MG-132, A cell-permeable, potent, reversible proteasome inhibitor (Ki = 4 nM).
Sigma-Aldrich
Anti-β-actina monoclonal antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-TREM-2 Antibody, clone 78, clone 78, from rat